Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 543-555

  De Buck, Stefan S ^a   Jakab, Annamaria ^a   Boehm, Markus ^a   Bootle, Douglas ^a   Juric, Dejan ^b   Quadt, Cornelia ^a   Goggin, Timothy K ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

BYL719; cancer; phosphoinositide 3 kinase; population pharmacokinetics; RECIST; transit compartment

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; ENDOXIFEN; TAMOXIFEN; ENZYME INHIBITOR; NVP-BYL719; PHOSPHATIDYLINOSITOL 3 KINASE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG METABOLISM; ELIMINATION HALF-LIFE; ENZYME ACTIVITY; FEMALE; HUMAN; LIMIT OF QUANTITATION; NONLINEAR SYSTEM; PHENOTYPE; POPULATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TISSUE DISTRIBUTION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; PHOSPHATIDYLINOSITOL 3-KINASES; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84906510657     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12378     Document Type: Article

References (34)

1. Engelman JA, Luo J, Cantley LC,. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619. (Pubitemid 44100518)
2. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
3. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.
4. Fruman DA, Meyers RE, Cantley LC,. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507. (Pubitemid 28411136)
5. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD,. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675. (Pubitemid 33096187)
6. Okkenhaug K, Vanhaesebroeck B,. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003; 3: 317-330. (Pubitemid 37328684)
7. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T, Omata M,. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-4567. (Pubitemid 40740791)
8. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS,. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65: 10992-11000. (Pubitemid 41713369)
9. Liu Z, Roberts TM,. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006; 5: 675-677.
10. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE,. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
11. Brognard J, Clark AS, Ni Y, Dennis PA,. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997. (Pubitemid 32720961)
12. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB,. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092. (Pubitemid 34160292)
13. Liu P, Cheng H, Roberts TM, Zhao JJ,. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
14. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B,. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-666. (Pubitemid 351769296)
15. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D,. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-138.
16. Brana I, Siu LL,. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012; 10: 161.
17. Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J, Aichholz R, Hamon J, Fabbro D, Caravatti G,. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 2013; 23: 3741-3748.
18. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell JC, Berlin JD, Middleton MR, Bootle D, Boehm M, Schmitt A, Rouyrre N, Quadt C, Baselga J,. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research: March 31-April 4 2012.
19. Zawalich WS, Zawalich KC,. A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats. Endocrinology 2000; 141: 3287-3295. (Pubitemid 32269017)
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J,. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J,. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000; 40: 1399-1418.
22. Lesko LJ, Rowland M, Peck CC, Blaschke TF,. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000; 17: 1335-1344. (Pubitemid 32109484)
23. Available at http://clinicaltrials.gov/show/NCT01219699 (last accessed 14 April 2014).
24. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-726. (Pubitemid 47477040)
25. Nerella NG, Block LH, Noonan PK,. The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model. Pharm Res 1993; 10: 1031-1036. (Pubitemid 23211428)
26. Shen J, Boeckmann A, Vick A,. Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J Pharmacokinet Pharmacodyn 2012; 39: 251-262.
27. Data on file at Novartis Institutes for Biomedical Research. Drug metabolism and Pharmacokinetics (DMPK) Europe, Basel, Switzerland.
28. Bruno R, Claret L,. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 2009; 86: 136-138.
29. Claret L, Girard P, Hoff PM, Van CE, Zuideveld KP, Jorga K, Fagerberg J, Bruno R,. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009; 27: 4103-4108.
30. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, Holford NH,. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 4213-4218.
31. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J,. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009; 86: 167-174.
32. Stein A,. Dynamic models of metastatic tumor growth. 27th Annual Workshop on Mathematical Problems in Industry, New Jersey Institute of Technology, June 13-17, 2011 Available at http://eaton.math.rpi.edu/Faculty/Schwendeman/Workshop/ MPIReports/2011/Novartis11.pdf (last accessed 14 April 2014).
33. Eto K, Yamashita T, Tsubamoto Y, Terauchi Y, Hirose K, Kubota N, Yamashita S, Taka J, Satoh S, Sekihara H, Tobe K, Iino M, Noda M, Kimura S, Kadowaki T,. Phosphatidylinositol 3-kinase suppresses glucose-stimulated insulin secretion by affecting post-cytosolic [Ca(2+)] elevation signals. Diabetes 2002; 51: 87-97. (Pubitemid 34517984)
34. Wilkinson GR,. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47. (Pubitemid 17048545)